Newsroom

TORONTO--(BUSINESS WIRE)--VerticalScope Holdings Inc. (“VerticalScope” or the “Company”) (TSX: FORA; OTCQX: VFORF) today announced that it has entered into agreements with two frontier AI labs. Under the agreements, VerticalScope will make available a select portion of community content for use in connection with the counterparties’ AI models and products. The Company expects to begin recognizing revenue under the agreements in the fourth quarter of 2026. The agreements also provide for two pot...

DRESDE, Allemagne--(BUSINESS WIRE)--Sparxity, acteur de référence du calcul sparse-native, annonce aujourd’hui la clôture de son tour de série A, qui porte à 90 millions de dollars le financement cumulé obtenu par son équipe. Le tour est mené par ICM HPQC Fund et rejoint par des investisseurs tels que Lockheed Martin Ventures, GlobalFoundries, GS Futures, Cloudberry Ventures, TGFS et l'EIC Fund. Le financement comprend également des investissements providentiels de dirigeants IA du TIME100, Ric...

TORONTO--(BUSINESS WIRE)--VerticalScope Holdings Inc. (“VerticalScope” or the “Company”) (TSX: FORA; OTCQX: VFORF), a technology company that has built and operates a cloud-based digital platform for online enthusiast communities, today announced financial results for the third quarter ended September 30, 2026 ("Q3" or "the quarter"). “We delivered higher profitability in Q3, driven by the strength of our enthusiast communities, disciplined cost management and consistent cash generation,” said...

ST. JOHN’S, Newfoundland and Labrador--(BUSINESS WIRE)--Altius Minerals Corporation (TSX: ALS; OTCQX: ATUSF) (“Altius” or the “Corporation”) reports its third quarter revenue of $19.6 million compared to $17.2 million in Q3 2025. Net earnings of $10.1 million ($0.17 per share) compares to net earnings of $264.9 million ($5.72 per share) in Q3 2025. Q3 2026 net earnings reflect higher revenues and higher expenses including costs of sales, general and administrative, share based compensation and...

BUENOS AIRES, Argentina--(BUSINESS WIRE)--Banco BBVA Argentina S.A. (NYSE; BYMA; MAE: BBAR; LATIBEX: XBBAR) today announced that it will report its Third Quarter 2026 financial results. Earnings Release Tuesday, Nov 24, 2026 Time: After market close Conference Call Wednesday, Nov 25, 2026 Time: 12:00 p.m. Buenos Aires time – (10:00 a.m. EST) Quiet Period From Tuesday, Nov 10, through Tuesday, Nov 24, 2026 Executives Ms. Carmen Morillo Arroyo, CFO Mr. Diego Cesarini, Head of ALM & Investor R...

MINNEAPOLIS--(BUSINESS WIRE)--Graco Inc. (NYSE: GGG) today announced that it has entered into an accelerated share repurchase (“ASR”) agreement with Bank of America, N.A. to repurchase $600 million of the Company’s shares of common stock. The ASR represents approximately 5% of Graco’s outstanding shares and will be funded with cash on hand and borrowings under the Company’s existing revolving credit facility. Under the ASR agreement, Graco will make an upfront payment of $600 million and expect...

SEATTLE--(BUSINESS WIRE)--Today, the Board of Directors of WaFd, Inc. (Nasdaq: WAFD) (the “Company”) announced a regular cash dividend of 27 cents per share. The dividend will be paid December 4, 2026, to common shareholders of record as of November 20, 2026. This will be the Company’s 175th consecutive quarterly cash dividend. WaFd, Inc. is the parent company of WaFd Bank, a federally insured Washington state chartered commercial bank that operates branches in Washington, Oregon, Idaho, Utah,...

威斯康星州麦迪逊--(BUSINESS WIRE)--(美国商业资讯)-- 美国食品药品监督管理局(FDA)已批准Promega OncoMate® MSI Dx分析系统作为Merck（在美国和加拿大以外称为MSD）抗PD-1疗法KEYTRUDA®的伴随诊断试剂，用于识别微卫星高度不稳定(MSI-H)实体瘤患者。 OncoMate® MSI Dx分析系统是一种基于聚合酶链反应(PCR)的检测方法，旨在评估实体瘤组织中的MSI状态。MSI状态可用于指导治疗决策，支持精准肿瘤治疗策略的实施。 Promega全球临床市场总监Alok Sharma表示：“此次批准体现了我们致力于提供有意义的诊断进步，并按最高质量和监管标准进行开发。我们的检测能够为患者匹配最有可能使其获益的治疗方案，并与我们的制药合作伙伴以及使用检测结果的临床医生协同工作。” 此次批准得到了KEYTRUDA®的销售商Merck的合作支持。两家公司正携手推进个性化医疗，扩大诊断试剂的可及性，助力做出明智的临床治疗选择。 OncoMate® MSI Dx分析系统此前已获得FDA批准，是首款基于PCR的分子诊断试剂，用于识别可能需要...

威斯康辛州麥迪森--(BUSINESS WIRE)--(美國商業資訊)-- 美國食品藥物管理局(FDA)已核准Promega OncoMate® MSI Dx分析系統做為Merck（在美國和加拿大以外稱為MSD）抗PD-1療法KEYTRUDA®的伴隨式診斷試劑，用於辨識微衛星高度不穩定(MSI-H)實質腫瘤病患。 OncoMate® MSI Dx分析系統是一種以聚合酶鏈反應(PCR)為基礎的檢測方法，旨在評估實質腫瘤組織中的MSI狀態。MSI狀態可用於指導治療決策，支援精準腫瘤治療策略的實施。 Promega全球臨床市場總監Alok Sharma表示：「此次核准體現了我們致力於提供有意義的診斷進步，並按最高品質和監管標準進行開發。我們的檢測能夠為病患匹配最有可能使其獲益的治療方案，並與我們的製藥合作夥伴以及使用檢測結果的臨床醫生協同工作。」 此次核准得到了KEYTRUDA®的銷售商Merck的合作支援。兩家公司正攜手推進個人化醫療，擴大診斷試劑的可及性，協助做出明智的臨床治療選擇。 OncoMate® MSI Dx分析系統此前已獲得FDA核准，是首款以PCR為基礎的分子診斷試劑，用於辨...

BERKELEY, Calif.--(BUSINESS WIRE)--VIVERSE, the web-based game distribution platform from HTC, today announced the return of its global university hackathon, VIVERSE Spark. Running from November 9 through December 4, 2026, the competition invites university students around the world to bring their creative visions to life by building games and interactive experiences, with cash prizes available to winning teams. Building on the 2025 competition, VIVERSE Spark 2026 challenges students to build w...